



Ref: BHL/STEX 14/2026-27

Date: June 26, 2026

BSE Limited Phiroze Jeejeebhoy Towers Dalal Street Mumbai – 400 001	National Stock Exchange of India Limited 5 th Floor, Exchange Plaza, Bandra Kurla Complex Bandra (East) Mumbai-400051
Scrip Code: 539872	Symbol: BAJAJHCARE

Dear Sir/Madam,

Subject: Intimation under Regulation 30 of the SEBI (LODR) Regulations, 2015

We wish to inform you that Bajaj Healthcare Limited has received a recommendation from the Subject Expert Committee (SEC) (Neurology & Psychiatry) of the Central Drugs Standard Control Organisation (CDSCO) for the grant of permission to manufacture and market of Cenobamate Tablets 12.5mg, 25mg, 50mg, 100mg, 150mg & 200mg.

The press release issued by the Company in this regard is enclosed herewith for your information.

Kindly take the same on record.

Thanking You,

For and Behalf of Bajaj Healthcare Limited

Monica Tanwar
Company Secretary & Compliance Officer



Investor Release

Bajaj Healthcare becomes the first in India to secure SEC recommendation for manufacture and marketing of Cenobamate Tablets

Mumbai, 26th June 2026: Bajaj Healthcare Limited is pleased to announce that it has become the first company in India to secure the Subject Expert Committee (SEC) recommendation for Cenobamate Tablets. The SEC of the Central Drugs Standard Control Organisation (CDSCO) has recommended for grant of approval for manufacturing and marketing of Cenobamate Tablets in strengths of 12.5 mg, 25 mg, 50 mg, 100 mg, 150 mg and 200 mg.

Cenobamate is a next-generation antiseizure medication developed for the treatment of partial-onset seizures in adults. Cenobamate offers an innovative approach to seizure management. Clinical studies have demonstrated significant seizure reduction and high seizure freedom rates in patients with inadequately controlled epilepsy, making it an important advancement in the evolving landscape of epilepsy treatment.

Speaking at the occasion Mr. Anil Jain, Managing Director, Bajaj Healthcare Limited, said –

“This approval represents a significant regulatory milestone for Bajaj Healthcare. It reflects the progress we have made in the development of Cenobamate Tablets and reinforces our commitment to expanding our portfolio of differentiated CNS therapies. We will continue to work closely with the regulatory authorities towards obtaining the necessary approvals and remain well-positioned to manufacture and commercialize the product, while further strengthening Bajaj Healthcare's position in the specialty pharmaceuticals segment.”

About Bajaj Healthcare Ltd:

Bajaj Healthcare Limited is a leading manufacturer of APIs, Intermediates and Formulations. Established in 1993, it has built a strong reputation for delivering high-quality pharmaceutical products, nutraceuticals across various therapies. The Company operates state-of-the-art manufacturing facilities that are designed to meet the requirements of both regulated and emerging markets. With a strong global presence, BHL serves customers across Europe, USA, Australia, Middle East, and South America.



Contact Details

Bajaj Healthcare Ltd	Investor Relations: MUFG Intime India Pvt. Ltd.
CIN: L99999MH1993PLC072892	Name: Ms. Prachi Ambre/ Mr. Irfan Raeen
Name: Mr. Anil Jain, MD	Email: prachi.ambre@in.mpms.mufg.com / irfan.raeen@in.mpms.mufg.com
Email: investors@bajajhealth.com	Meeting Request Link – Link

Safe Harbor Statement

Any forward-looking statements about expected future events, financial and operating results of the Company are based on certain assumptions which the Company does not guarantee the fulfilment of. These statements are subject to risks and uncertainties. Actual results might differ substantially or materially from those expressed or implied. Important developments that could affect the Company's operations include a downtrend in the industry, global or domestic or both, significant changes in political and economic environment in India or key markets abroad, tax laws, litigation, labour relations, exchange rate fluctuations, technological changes, investment and business income, cash flow projections, interest, and other costs. The Company does not undertake any obligation to update forward-looking statements to reflect events or circumstances after the date thereof.